Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.

Logue OC, Mahdi F, Chapman H, George EM, Bidwell GL 3rd.

J Am Heart Assoc. 2017 Dec 8;6(12). pii: e007216. doi: 10.1161/JAHA.117.007216.

2.

Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia.

Wallace B, Peisl A, Seedorf G, Nowlin T, Kim C, Bosco J, Kenniston J, Keefe D, Abman SH.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):776-787. doi: 10.1164/rccm.201707-1371OC.

PMID:
29268623
3.

Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Hoeres T, Wilhelm M, Smetak M, Holzmann E, Schulze-Tanzil G, Birkmann J.

Clin Exp Immunol. 2018 Apr;192(1):54-67. doi: 10.1111/cei.13090. Epub 2018 Jan 4.

PMID:
29235095
4.

Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1.

Eslani M, Putra I, Shen X, Hamouie J, Afsharkhamseh N, Besharat S, Rosenblatt MI, Dana R, Hematti P, Djalilian AR.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5507-5517. doi: 10.1167/iovs.17-22680.

5.

Anti‑angiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt‑1.

Li G, Miao F, Zhu J, Chen Y.

Mol Med Rep. 2017 Nov;16(5):5799-5806. doi: 10.3892/mmr.2017.7310. Epub 2017 Aug 22.

6.

The Soluble VEGF Receptor sFlt-1 Contributes to Impaired Neovascularization in Aged Mice.

Zhao G, Cheng XW, Piao L, Hu L, Lei Y, Yang G, Inoue A, Ogasawara S, Wu H, Hao CN, Okumura K, Kuzuya M.

Aging Dis. 2017 May 2;8(3):287-300. doi: 10.14336/AD.2016.0920. eCollection 2017 May.

7.

Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy.

Teixeira SC, Lopes DS, Gimenes SN, Teixeira TL, da Silva MS, Brígido RT, da Luz FA, da Silva AA, Silva MA, Florentino PV, Tavares PC, Dos Santos MA, Ávila VM, Silva MJ, Elias MC, Mortara RA, da Silva CV.

Sci Rep. 2017 Mar 21;7:44978. doi: 10.1038/srep44978.

8.

A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands.

Clegg LE, Mac Gabhann F.

PLoS Comput Biol. 2017 Mar 20;13(3):e1005445. doi: 10.1371/journal.pcbi.1005445. eCollection 2017 Mar.

9.

Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.

Abou-Fayçal C, Hatat AS, Gazzeri S, Eymin B.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E383. doi: 10.3390/ijms18020383. Review.

10.

Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity.

Liu Z, Liu G, Zhang GL, Li J, He YQ, Zhang SS, Wang Y, He WY, Cheng GH, Yang X, Xu J, Wang J.

Oncotarget. 2016 Oct 18;7(42):68473-68488. doi: 10.18632/oncotarget.12067.

11.

Activation of dengue virus-specific T cells modulates vascular endothelial growth factor receptor 2 expression.

Rattanamahaphoom J, Leaungwutiwong P, Limkittikul K, Kosoltanapiwat N, Srikaitkhachorn A.

Asian Pac J Allergy Immunol. 2017 Sep;35(3):171-178. doi: 10.12932/AP0810.

12.

Gene delivery nanoparticles to modulate angiogenesis.

Kim J, Mirando AC, Popel AS, Green JJ.

Adv Drug Deliv Rev. 2017 Sep 15;119:20-43. doi: 10.1016/j.addr.2016.11.003. Epub 2016 Nov 30. Review.

PMID:
27913120
13.

Association of sFlt-1 and worsening psychopathology in relatives at high risk for psychosis: A longitudinal study.

Lizano PL, Yao JK, Tandon N, Mothi SS, Montrose DM, Keshavan MS.

Schizophr Res. 2017 May;183:75-81. doi: 10.1016/j.schres.2016.11.015. Epub 2016 Nov 15.

PMID:
27863935
14.

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration.

Li W, Dong L, Ma M, Hu B, Lu Z, Liu X, Liu J, Li X.

Drug Des Devel Ther. 2016 Oct 19;10:3415-3423. eCollection 2016.

15.

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.

Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S, Lacal PM.

Oncotarget. 2016 Nov 8;7(45):72868-72885. doi: 10.18632/oncotarget.12108.

16.

Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies.

Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao L, Xu H, Cui Y.

Reprod Biol Endocrinol. 2016 Sep 20;14(1):61. doi: 10.1186/s12958-016-0191-8.

17.

Spontaneous In Vivo Chondrogenesis of Bone Marrow-Derived Mesenchymal Progenitor Cells by Blocking Vascular Endothelial Growth Factor Signaling.

Marsano A, Medeiros da Cunha CM, Ghanaati S, Gueven S, Centola M, Tsaryk R, Barbeck M, Stuedle C, Barbero A, Helmrich U, Schaeren S, Kirkpatrick JC, Banfi A, Martin I.

Stem Cells Transl Med. 2016 Dec;5(12):1730-1738. Epub 2016 Jul 26.

18.

Pigment epithelium-derived factor (PEDF): a novel trophoblast-derived factor limiting feto-placental angiogenesis in late pregnancy.

Loegl J, Nussbaumer E, Hiden U, Majali-Martinez A, Ghaffari-Tabrizi-Wizy N, Cvitic S, Lang I, Desoye G, Huppertz B.

Angiogenesis. 2016 Jul;19(3):373-88. doi: 10.1007/s10456-016-9513-x. Epub 2016 Jun 8.

19.

Aberrant Pulmonary Vascular Growth and Remodeling in Bronchopulmonary Dysplasia.

Alvira CM.

Front Med (Lausanne). 2016 May 20;3:21. doi: 10.3389/fmed.2016.00021. eCollection 2016. Review.

20.

Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells.

Miyake T, Kumasawa K, Sato N, Takiuchi T, Nakamura H, Kimura T.

Sci Rep. 2016 Apr 22;6:24853. doi: 10.1038/srep24853.

Supplemental Content

Support Center